publication date: Dec. 6, 2013
Wall Street Analyst Who Sounded Alarm  Over Prostate Cancer Drug Provenge In JNCI  Settles with SEC Over Shorting Dendreon Stock An Earmark in the Making: NCI Urged to Boost Gastric Cancer Funding Johnson to Leave NCI Office of Communications FDA Expands Nexavar Indication to Include Thyroid Cancer

Download the PDF

Documents referenced in this issue of The Cancer Letter can be found here

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.